Nano-engineered mesenchymal stem cells as targeted therapeutic carriers

Area of Science:

• Biomedical Engineering
• Cancer Therapeutics
• Nanotechnology

Background:

• Poor drug penetration into deep-seated solid tumors limits anticancer drug efficacy.
• Mesenchymal stem cells (MSCs) possess inherent tumor-homing and drug-resistant properties.
• Developing targeted drug delivery systems is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To develop and evaluate nano-engineered MSCs as targeted carriers for anticancer agents.
• To assess the in vitro cytotoxicity and in vivo biodistribution of nano-engineered MSCs.
• To determine if nanoparticle incorporation affects MSC viability, differentiation, or migration.

Main Methods:

• Human MSCs were engineered by incorporating drug-loaded polymeric nanoparticles.
• In vitro cytotoxicity was assessed using A549 lung adenocarcinoma and MA148 ovarian cancer cells.
• In vivo biodistribution was evaluated in an orthotopic A549 lung tumor model following intravenous injection.

Main Results:

• Nano-engineered MSCs exhibited dose-dependent cytotoxicity against cancer cells in vitro.
• Incorporation of nanoparticles did not impair MSC viability, differentiation, or migration.
• In vivo studies showed selective accumulation and retention of nano-engineered MSCs in lung tumors, unlike non-specific nanoparticle biodistribution.

Conclusions:

• Nano-engineered MSCs are a feasible platform for delivering high concentrations of anticancer agents.
• This approach leverages MSCs' tumor-targeting and drug-resistance properties for enhanced cancer therapy.
• The developed nano-engineered MSCs demonstrate potential for improving therapeutic efficacy in solid tumors.